Check Point Software Reports 2026 Third Quarter Financial Results

Check Point reported Q3 2026 revenue of $669.8 million, down 1% year over year, while security subscriptions grew 11% to $338.6 million and RPO rose 5% to $2.5 billion. GAAP EPS was $1.82 and non-GAAP EPS was $2.49, both down sharply year over year due largely to a roughly $1.47-per-share tax benefit in Q3 2025; excluding that benefit, both measures increased 1%. The CEO said revenue likely reached a trough and expects gradual improvement from Q4, while noting recovery is taking longer than anticipated. The company repurchased 2.5 million shares for approximately $325 million during the quarter.

Analysis

The underlying read-through is weaker than the headline-adjusted EPS suggests: recurring subscriptions are growing, but legacy products/licenses and maintenance are contracting, leaving total revenue roughly flat. This mix shift can be healthy if customers are migrating onto higher-value subscriptions, but RPO growth of only 5% provides limited confirmation that subscription momentum will accelerate soon. Verify billings, renewal rates, and product-level bookings on the call; reported RPO alone does not settle the migration-versus-demand question.

Profitability also has support that may not fully represent durable operating leverage. Israeli R&D incentives reduced quarterly R&D expense by $25 million; confirm eligibility, cash realization, and recurrence before capitalizing the benefit. The prior-year tax settlement distorts the EPS comparison, while the $2 billion convertible issuance means the larger cash balance is not purely internally generated. Continued buybacks support per-share results but compete with potential conversion dilution; monitor the note terms and diluted share count.

Near term, the CEO’s “trough” assertion is the main catalyst, not a demonstrated inflection. Q4 guidance and evidence of improving bookings could support a rerating; another quarter of weak total revenue or soft RPO would undermine it. Over 6–18 months, sustained subscription growth could offset erosion in older products, but the transition is not yet validated. The contrarian risk is that investors focus too heavily on the tax-distorted EPS decline and overlook subscription growth; equally, the company’s recovery narrative may be priced ahead of the modest backlog signal. Current valuation and call guidance are needed before sizing an outright short.

Key Decisions for Investors

• Keep CHKP underweight pending the conference call; do not trade the reported EPS decline in isolation. Reassess on Q4 revenue guidance, subscription bookings, and management’s evidence behind improving leading indicators.
• If CHKP rallies on the “revenue trough” message without stronger bookings or RPO commentary, consider a small relative-value short in CHKP versus a diversified cybersecurity exposure. Define the thesis as fading relative performance, not a sector-wide cyber short; avoid setting a price target without current valuation data.
• Watch for confirmation that the $25 million quarterly R&D credit is recurring and monetizable. If the benefit proves temporary or cash realization is delayed, lower confidence in near-term margin support; if it is durable, do not treat the full reported margin weakness as structural.
• Falsifiers for the cautious view: accelerating subscription growth accompanied by improving RPO/bookings, credible Q4-to-2027 revenue acceleration, and stable diluted share count despite the convertible notes. Conversely, another quarter of flat-to-down revenue or weaker backlog would strengthen the underweight thesis.